Pharmaceutical

CD123-targeted CAR-NK by Chongqing Precision Biotech for Natural Killer Cell Lymphomas: Likelihood of Approval

CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Natural Killer Cell Lymphomas.

Oct 3, 2023 - 20:00
CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Natural Killer Cell Lymphomas.
Read the original article

Tags:

Previous Article

MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval

Next Article

BGB-26808 by BeiGene for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biocytogen and Radiance partner for bispecific antibody-drug conjugate

Biocytogen and Radiance partner for bispecific antibody...

Jan 9, 2024

Tracking the Drug Trail

Tracking the Drug Trail

Apr 16, 2023

CJ-15314 by HK inno.N for Atopic Dermatitis (Atopic Ecz...

Jul 7, 2023